Exelixis Reaches Settlement for Cabometyx Patent Litigation

Biotechnology firm Exelixis said it entered into a settlement concerning patent litigations brought against Cipla.

• The settlement resolves a pair of patent litigations concerning Cipla’s abbreviated new drug application seeking approval to market generic versions of cabometyx (cabozantinib) tablets prior to the expiration of the applicable patents
  • NOTE: March 2023, Exelixis Sues Cipla to Block Cabometyx Copies Till at Least 2030
• Exelixis will grant Cipla a license to market generic versions of cabometyx in the US beginning on January 1, 2031, if approved by the FDA
• The agreement is confidential and subject to review by the FTC and the ...